Open Label, Safety and Efficacy Study of Topical Investigational Drug to Treat Patients With Psoriasis

Incyte

Status and phase: Completed; Phase 2

Conditions: Psoriasis

Treatments: Drug: Ruxolitinib

Study type: Interventional

Funder types: Industry

Identifiers

NCT00617994

INCB 18424-202

Details and patient eligibility

About

This will be an open label study of ruxolitinib topical cream applied to 2 - 20% BSA in patients with active, stable plaque psoriasis.

Enrollment: 25 patients

Sex: All

Ages: 18 to 65 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Subjects must have psoriatic lesions measuring protocol specific BSA

Exclusion criteria

• Lesions solely involving the palms of the hands, the soles of the feet, the intertriginious areas, the scalp or the face
• Pustular psoriasis or erythroderma

Trial design

Primary purpose: Treatment

Allocation: Non-Randomized

Interventional model: Parallel Assignment

Masking: None (Open label)

---

25 participants in 3 patient groups

Group A

Experimental group

Description:

Patients with active stable plaque psoriasis treated with topical cream application on lesions involving a small percent BSA.

Treatment:

Drug: Ruxolitinib

Group B

Experimental group

Description:

Patients with active stable plaque psoriasis treated with topical cream application on lesions involving a larger percent BSA than Cohort 1.

Treatment:

Drug: Ruxolitinib

Group C

Experimental group

Description:

Patients with active stable plaque psoriasis treated with topical cream application on lesions involving a larger percent BSA than Cohort 2.

Treatment:

Drug: Ruxolitinib